Press Releases
Jul 26, 2024
Astellas Receives Positive CHMP Opinion for Zolbetuximab in Combination with Chemotherapy for Treatment of Advanced Gastric and Gastroesophageal Junction Cancer

- If approved by the European Commission, zolbetuximab would become the first and only CLDN18.2-targeted therapy approved in the European Union - A decision on the EU marketing authorization is...

Jul 26, 2024
Astellas Receives Positive CHMP Opinion for PADCEV™ (enfortumab vedotin) in combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer

- If approved, enfortumab vedotin in combination with pembrolizumab will be the first and only treatment to offer an alternative to platinum-containing chemotherapy, the current standard of care...

Jul 22, 2024
Astellas and Graduate School of Medicine / Faculty of Medicine, Osaka University Enter into Research Collaboration to Develop Pluripotent Stem Cell-Derived Cartilage Organoid Cell Therapy

- Collaborative Research on Innovative Cartilage Organoid Cell Therapy for Intervertebral Disc Degenerative Disease using Astellas' Universal Donor Cell Technology - TOKYO and OSAKA, Japan, July...

EXPLORE ALL US PRESS RELEASES

Articles
Jul 18, 2024
Astellas Legal and IP Division Takes Action to Advance Diversity, Equity and Inclusion

Diversity, equity and inclusion (DEI) have always been critically important to the Astellas Legal and IP Division. Since 2017, the Astellas Legal and IP Division has actively worked to promote DEI...

Feb 8, 2024
From Recurrence to Perseverance: Jim's Prostate Cancer Story

As a civilian partner working for the Army for many years following his time in Vietnam, Jim didn’t suspect anything was amiss when he went for his annual health exam in 2006. However, during...

Dec 15, 2023
Astellas Recognized for its Support of the LGBTQ+ Community through Human Rights Campaign Foundation’s Annual Corporate Equality Index

Astellas is proud to be featured on the Human Rights Campaign Foundation’s (HRC) annual Corporate Equality Index (CEI) for its continued support of the LGBTQ+ community within the workplace....

EXPLORE ALL ARTICLES

Stay Connected

Get only the email alerts you want.

Subscribe

Media Contacts

 

For media inquiries and reporter requests, please click here to fill out a request form.

Our communications team will respond to verified media requests within 24-48 hours as appropriate.

If you are not a reporter and need assistance, please visit our contact us page that includes information for patients, healthcare providers and researchers.

 

Download Fact Sheet

Download Fact Sheet

Sustainability

Sustainability

Investors

Investors

Explore U.S. Products

Explore U.S. Products